U.S. Markets open in 8 hrs 39 mins

Imagine Owning MEI Pharma (NASDAQ:MEIP) While The Price Tanked 63%

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example the MEI Pharma, Inc. (NASDAQ:MEIP) share price dropped 63% over five years. We certainly feel for shareholders who bought near the top. And some of the more recent buyers are probably worried, too, with the stock falling 48% in the last year. Shareholders have had an even rougher run lately, with the share price down 30% in the last 90 days.

Check out our latest analysis for MEI Pharma

Given that MEI Pharma didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.


You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

NasdaqCM:MEIP Income Statement, July 8th 2019

If you are thinking of buying or selling MEI Pharma stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Investors in MEI Pharma had a tough year, with a total loss of 48%, against a market gain of about 7.2%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 18% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

We will like MEI Pharma better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.